Azura Ophthalmics announced it has received positive feedback from a pre-New Drug Application (NDA) meeting with the US Food ...

New grading scales for ocular adverse events in oncology improve clarity and provide drug-dose-modification recommendations, ...

Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...

The authors wrote that early diagnosis, adherence to prolonged management, and constant monitoring can allow the cornea to ...

The US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to EyeYon Medical for ...

"Lubricating drops" is proposed as a more accurate term, reflecting their primary function of providing lubrication and ...

BCVA is inadequate for detecting visual disturbances in conditions like MacTel, which initially affect the parafoveal region.

Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over ...

The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, ...

In the second part, the discussion turns to emerging DED therapies that target tear function and ocular surface homeostasis.

Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

Alcon increases its acquisition offer for STAAR Surgical, emphasizing a final deal amid shareholder debates and delays in the ...